Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

Presentation AHA 2016

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Presenter: Dirk J. van Veldhuisen

November 16, 2016

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

Presentation AHA 2016

Arterial Revascularization Trial (ART)

Presenter: David P. Taggart

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Presentation

AHA Late Breaking Trials: What's more appropriate? IVUS or appropriate use criteria?

Presenter: Gregg W. Stone

January 19, 2016

Presentation TCT 2015

Intervention for Tricuspid Regurgitation: What Do the Guidelines Say? (ACC/AHA and ESC/EACTS)

Presenter: Rebecca T. Hahn, Joachim Schofer, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

What Defines Severe MR Post-AHA/ACC Guidelines?

Presenter: Jeroen J. Bax, Paul A. Grayburn

October 15, 2015

Presentation TVT 2015

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Disagree?

Presenter: Gregg W. Stone, Alec S. Vahanian, John D. Carroll

June 05, 2015

Presentation TVT 2015

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Agree?

Presenter: Gregg W. Stone, Alec S. Vahanian, Allan Schwartz

June 05, 2015

Presentation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Presenter: Gregg W. Stone

December 01, 2014

Presentation AHA 2014

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Presenter: Dean J. Kereiakes

November 16, 2014

Presentation AHA 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presenter: C.Kaiser

November 16, 2014

Presentation AHA 2014

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Presenter: S. van Diepen

November 16, 2014

Presentation TCT 2014

Guideline Update: Aortic and Mitral Valve Disease and the 2014 AHA/ACC Guideline for Valvular Heart Disease

Presenter: Blase A. Carabello, George D. Dangas, Patrick T. O'Gara

September 15, 2014

Presentation TCT 2014

ASA/AHA Guidelines 2014: PFO Closure for Cryptogenic Stroke Is Now Class III LOE A! Is This the Final Word from the Neurology Community?

Presenter: Matthew J. Price, Mark Reisman, Sheldon Goldberg, David E. Thaler

September 13, 2014

Advertisement

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Arterial Revascularization Trial (ART)

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

FUnctional Testing Underlying REvascularization: The FUTURE trial

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

AHA Late Breaking Trials: What's more appropriate? IVUS or appropriate use criteria?

Intervention for Tricuspid Regurgitation: What Do the Guidelines Say? (ACC/AHA and ESC/EACTS)

What Defines Severe MR Post-AHA/ACC Guidelines?

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Disagree?

ESC/EACTS 2012 and ACC/AHA 2014 Valvular Heart Disease Guidelines: Where Do They Agree?

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Guideline Update: Aortic and Mitral Valve Disease and the 2014 AHA/ACC Guideline for Valvular Heart Disease

ASA/AHA Guidelines 2014: PFO Closure for Cryptogenic Stroke Is Now Class III LOE A! Is This the Final Word from the Neurology Community?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content